David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay, shared on LinkedIn:
“Testing for BRAF V600E in all NSCLC patients is crucial, regardless of smoking status!
Great efficacy with E+B or D+T combinations, which remain preferred option over chemo-IO 1L. Far too many patients are still missing out on the standard-of-care targeted therapy BRAFi+MEKi.”
You can also read:
